Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial

Keyphrases

• Timolol 100%
• Randomized Clinical Trial 100%
• Hereditary Hemorrhagic Telangiectasia 100%
• Intranasal 100%
• Epistaxis 100%
• Thermosensitive Gel 100%
• Placebo Groups 41%
• Epistaxis Severity Score 41%
• Placebo 25%
• Clinical Global Impression 25%
• Hemoglobin Level 16%
• Outcome Scores 16%
• Nasal Outcome 16%
• Inclusion Criteria 8%
• Tertiary Care Hospital 8%
• Placebo-controlled 8%
• Adverse Events 8%
• Twice Daily 8%
• Minimal Clinically Important Difference 8%
• Standard of Care 8%
• Trial Registration 8%
• Moderate to Severe 8%
• Medical Therapy 8%
• Highly Effective 8%
• Quality of Life 8%
• Clinical Diagnosis 8%
• Exclusion Criteria 8%
• Antiangiogenic 8%
• Topical Therapy 8%
• Medication Use 8%
• Primary Outcome Measure 8%
• Nasal 8%
• Beta-blockers 8%
• Median Range 8%
• Genetic Diagnosis 8%
• Anticoagulants 8%
• Antiplatelet Therapy 8%
• Clinically Meaningful Improvement 8%
• Clinically Meaningful Difference 8%
• Thermosensitive 8%
• Effect Estimates 8%
• Nostril 8%
• Nosebleed 8%
• Moisturizer 8%
• Severe Epistaxis 8%
• Fibrinolytic Therapy 8%
• Timolol Gel 8%
• Epistaxis Treatment 8%
• Change Range 8%
• Nasal Hygiene 8%

Medicine and Dentistry

• Randomized Clinical Trial 100%
• Hereditary Hemorrhagic Telangiectasia 100%
• Epistaxis 100%
• Timolol 100%
• Placebo 47%
• Clinical Global Impression 15%
• Drug Therapy 10%
• Tertiary Care 5%
• Adverse Event 5%
• Combination Therapy 5%
• Quality of Life 5%
• Antiplatelet 5%
• Antiangiogenic 5%
• Contraindication 5%
• Topical Treatment 5%
• Fibrinolytic Therapy 5%
• Anticoagulant 5%
• Minimal Clinically Important Difference 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Timolol 100%
• Randomized Clinical Trial 100%
• Rendu Osler Weber Disease 100%
• Epistaxis 100%
• Placebo 47%
• Combination Therapy 5%
• Adverse Event 5%
• Antiangiogenic 5%
• Anticoagulant Agent 5%
• Antiplatelet 5%
• Fibrinolytic Therapy 5%